We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
[<sup>18</sup>F]MFBG PET/CT outperforming [<sup>123</sup>I]MIBG SPECT/CT in the evaluation of neuroblastoma.
- Authors
Wang, Peipei; Li, Tuo; Liu, Zhikai; Jin, Mei; Su, Yan; Zhang, Jingjing; Jing, Hongli; Zhuang, Hongming; Li, Fang
- Abstract
Purpose: Iodine 123 labeled meta-iodobenzylguanidine ([123I]MIBG) scan with SPECT/CT imaging is one of the most commonly used imaging modalities in the evaluation of neuroblastoma. [18F]-meta-fluorobenzylguanidine ([18F]MFBG) is a novel positron emission tomography (PET) tracer which was reported to have a similar biodistribution to [123I]MIBG. However, the experience of using [18F]MFBG PET/CT in the evaluation of patients with neuroblastoma is limited. This preliminary investigation aims to assess the efficacy of [18F]MFBG PET/CT in the evaluation of neuroblastomas in comparison to [123I]MIBG scans with SPECT/CT. Materials and methods: In this prospective, single-center study, 40 participants (mean age 6.0 ± 3.7 years) with history of neuroblastoma were enrolled. All children underwent both [123I]MIBG SPECT/CT and [18F]MFBG PET/CT studies. The number of lesions and the Curie scores revealed by each imaging method were recorded. Results: Six patients had negative findings on both [123I]MIBG and [18F]MFBG studies. Four of the 34 patients (11.8%) were negative on [123I]MIBG but positive on [18F]MFBG, while 30 patients were positive on both [123I]MIBG and [18F]MFBG studies. In these 34 patients, [18F]MFBG PET/CT identified 784 lesions while [123I]MIBG SPECT/CT detected 532 lesions (p < 0.001). The Curie scores obtained from [18F]MFBG PET/CT (11.32 ± 8.18, range 1-27) were statistically higher (p < 0.001) than those from [123I]MIBG SPECT/CT (7.74 ± 7.52, range 0-26). 30 of 34 patients (88.2%) with active disease on imaging had higher Curie scores based on the [18F]MFBG study than on the [123I]MIBG imaging. Conclusion: [18F]MFBG PET/CT shows higher lesion detection rate than [123I]MIBG SPECT/CT in the evaluation of pediatric patients with neuroblastoma. Clinical trial registration: Clinicaltrials.gov: NCT05069220 (Registered: 25 September 2021, retrospectively registered); Institute Review Board of Peking Union Medical College Hospital: ZS-2514
- Subjects
BEIJING (China); POSITRON emission tomography; NEUROBLASTOMA; COMPUTED tomography; CHILD patients; SINGLE-photon emission computed tomography
- Publication
European Journal of Nuclear Medicine & Molecular Imaging, 2023, Vol 50, Issue 10, p3097
- ISSN
1619-7070
- Publication type
Article
- DOI
10.1007/s00259-023-06221-4